COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?

Frontiers in Cardiovascular Medicine

article

Florian Zores¹  Mathieu E. Rebeaud² 

[1] Groupe Médical Spécialisé;Faculty of Biology and Medicine, University of Lausanne

关键词: COVID-19;    SARS-CoV-2;    ACE2;    angiotensin;    renin;    2019-nCoV;   

DOI  :  10.3389/fcvm.2020.00071

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Since its outbreak in December 2019, Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) has spread worldwide and is considered a pandemic. Coronavirus disease (COVID-19) can lead to acute respiratory distress syndrome (ARDS) or death. Many efforts have been made to identify risk factors predisposing to a severe issue. In the first SARS-CoV epidemic in 2002, hypertension was noted in 9/19 patients who died from SARS-CoV in Toronto (1). In the two largest cohorts of SARS-CoV-2 published, hypertension is the most common comorbidity in patients with severe disease or in those who died or were ventilated (2, 3). Nevertheless, these data are not adjusted for age, although age appears to be a strong predictor of adverse outcome (4) and hypertension is a very common finding in older patients. Finally, cohort studies only show correlation, not causality. In this paper, we hypothesize that the reductions in Angiotensin-Converting Enzyme 2 (ACE-2) observed in hypertension and obesity can explain many abnormalities observed in SARS-CoV-2 and question the role of treatments interfering with ACE2.

【 授权许可】

CC BY